Rationale: AMP-activated protein kinase (AMPK) is an important regulator of energy balance and signaling in the heart. Mutations affecting the regulatory ␥2 subunit have been shown to cause an essentially cardiacrestricted phenotype of hypertrophy and conduction disease, suggesting a specific role for this subunit in the heart.
sequences, all containing 2 pairs of highly conserved cystathionine ␤-synthase domains, which have been shown to be directly involved in the binding of adenine nucleotides. [5] [6] [7] In contrast, their N-terminal regions are highly variable, with ␥2 and ␥3 possessing different long N-terminal extensions compared with the shorter ␥1 isoform (Figure 1 ). The ␥2 and ␥3 N-terminal sequences appear to be unique in that they do not share sequence identity with each other nor with any known protein. No specific function for these N-terminal extensions has been reported.
In the heart, AMPK has an important role in the regulation of energy balance and in myocardial signaling. 8 In particular, it is activated during ischemia, where it plays a role in reducing ischemic injury by increasing glycolysis, 9, 10 and it remains activated during reperfusion when it has diverse effects on postischemic metabolism. 10, 11 It has also been shown to be activated during exercise 12 and by both volume and pressure overload. 13 Molecular genetic work has shown that mutations within the ␥2 subunit cause a severe compound cardiac phenotype of left ventricular hypertrophy, glycogen deposition, Wolff-Parkinson-White syndrome, and progressive conduction disease. 14 -17 Mutations in the genes encoding the other subunit isoforms of AMPK do not appear to cause this phenotype, suggesting that alteration of the function of heterotrimers containing the ␥2 subunit specifically cause this disease. 18 Because ␥2 is a minority isoform and is ubiquitously expressed, this phenotype suggests a specific role for this subunit in the heart. We hypothesized that the unique N-terminal region of the ␥2 subunit may play a role in determining substrate specificity in the heart or intracellular localization. We describe the results of a yeast 2-hybrid screen of a human cardiac cDNA library used to test this hypothesis, which showed that cardiac troponin I (cTnI) interacts with the unique N-terminal region of AMPK ␥2; we furthermore show that cTnI is a good in vitro AMPK substrate principally phosphorylated on Ser150 and that cTnI is phosphorylated in situ at the same residue on AMPK activation. Functionally, this modification results in an increase in the Ca 2ϩ sensitivity of contractile regulation and treatment of isolated cardiomyocytes with an AMPK activator increases contractility and prolongs relaxation.
Methods
An expanded Methods section is available in the online Data Supplement.
Human Heart cDNA Library Screening by Yeast 2-Hybrid Assay
The bait plasmid was constructed by cloning the sequence encoding amino acids 1 to 273 of AMPK␥2 (cDNA accession number NM 016203) in frame with the yeast GAL4 DNA-binding domain (DNA-BD) of the vector pGBKT7 and used to screen a pretransformed MATCHMAKER Human Heart cDNA Library (Clontech).
Protein Biochemistry
Recombinant human AMPK heterotrimers were purified and activated, 3, 19 and recombinant human contractile proteins were prepared according to our published methods. 20, 21 Commercial antibodies were used to detect AMPK ␣ Thr172 phosphorylation (Santa Cruz Biotechnology), total cTnI (Sigma Aldrich), and phosphorylation of Ser23/24 of cTnI (Cell Signaling Technology). For detection of cTnI Ser150 phosphorylation, a polyclonal antibody was generated against the phosphopeptide LRRVRIS(phos)ADAMMQA and purified with affinity cross-absorption with the nonphosphorylated peptide. 22 In vitro AMPK phosphorylation reactions were carried out and analyzed as previously described. 3 In vitro actin-tropomyosin-activated myosin ATPase activities were measured by our standard technique. 21
Mass Spectrometry
His-AMPK ␣1(1-312) was expressed and purified as previously reported, and activated using 15 nmol/L LKB1/STRAD/MO25 in 60 mmol/L HEPES-NaOH, pH 7.5, 3 mmol/L MgCl 2 , 3 mol/L Na 3 VO 4 , 1.2 mmol/L DTT, 500 mol/L ATP for 4 hours at 37°C. 22 Peptides (250 -270 mol/L), synthesized and purified as earlier described, 23 were incubated with 200 nmol/L activated His-AMPK ␣1 . All data were acquired on a linear trap/FTICR (LTQ FT Ultra) hybrid mass spectrometer equipped with an automated chipbased nanoESI source as described previously. 22 All reported M r values are most abundant masses.
Langendorff Perfusion and Global Ischemia Protocol
Male C57BL/6 mice were anesthetized with pentobarbital (300 mg/kg with 150 IU heparin, IP). After midline sternotomy, hearts were rapidly excised and retrogradely perfused at a constant pressure of 80 mm Hg with a modified Krebs-Henseleit buffer saturated with 95% O 2 and 5% CO 2 , and maintained at 37°C.
Hearts were immersed in a water-jacketed chamber containing Krebs-Henseleit buffer maintained at 37°C. After a period of 20-minute stabilization, hearts were subjected to either 30 minutes of global ischemia (ischemia group) or to an additional 30-minute period of normal perfusion (time control group) before freeze-clamping.
Measurement of Left Ventricular Myocyte Shortening and Ca 2؉ Transient
Left ventricular (LV) myocytes were isolated from C57BL/6 mice using a standard enzymatic dispersion technique. 24 
Results

Yeast 2-Hybrid Screen to Identify AMPK ␥2 Interactors
To identify proteins in the human heart that interact with the unique N-terminal extension of AMPK ␥2, a GAL4-based yeast 2-hybrid assay was undertaken to screen a human heart cDNA library, using the N-terminal 273 residues of AMPK ␥2 as bait. Eight clones were isolated that met the criteria of supporting growth in the presence of the bait plasmid under highest stringency conditions and of not producing autoactivation. Four of the clones (ANKRD1, FARP1, PSMD1, and SKIIP) were singly represented and the remaining 4 contained the full, in-frame sequence of TNNI3, which encodes cTnI (see the Table) . The isolated TNNI3 clones were composed of 3 independent clones with 11, 13 (represented twice), and 30 amino acids encoded before the cTnI sequence in the GAL4 fusion protein. cTnI is a thin-filament protein and is a key component of the Ca 2ϩ regulatory mechanism of myofilament contraction. 26, 27 It is also a well-characterized phosphoprotein; the modification of the serine pair at residues 23 and 24 is known to be of physiological importance in the regulation of cross-bridge kinetics and myocyte relaxation, 28, 29 and in vitro phosphorylation sites have been identified for, among others, protein kinase A, protein kinase C, protein kinase G, and p21-dependent protein kinase. 30
cTnI Is a Good In Vitro Substrate of AMPK
The finding that cTnI is a putative interactor with AMPK ␥2 suggests that AMPK complexes containing the ␥2 subunit may localize to the thin filament and/or that cTnI is a substrate for these complexes. To test the latter, in vitro phosphorylation experiments were carried out using purified recombinant human cTnI as substrate. These demonstrated that cTnI is indeed a strong substrate for recombinant ␣1␤1␥2 AMPK (Figure 2A , inset, lane 2) and is phosphor-ylated at a similar rate as the model substrate SAMS peptide ( Figure 2A ). Furthermore, cTnI is also phosphorylated at a comparable rate by ␣1␤1␥1 AMPK (Figure 2A inset, lane 3), showing that the putative interaction with the ␥2 subunit is not required for efficient in vitro phosphorylation of cTnI.
Phosphoamino acid analysis carried out on 32 P-labeled cTnI showed that phosphate was specifically incorporated into serine residues ( Figure 2B ).
Identification of AMPK Phosphorylation Sites on cTnI
A series of cTnI mutants with previously identified phosphorylation residues mutated to nonphosphorylatable aspartate residues was used to investigate the location of phosphate incorporation in the cTnI sequence. In experiments using ␣1␤1␥2 AMPK, cTnI with Ser42 and Ser44 (known protein kinase C sites) mutated was phosphorylated to a similar level as wild-type, as was cTnI with Thr143 (also a known protein kinase C site) mutated to aspartate ( Figure 2C ). However, Ser150Asp cTnI (31% of wild-type) and Ser23Asp/Ser24Asp cTnI (55% of wild-type) both showed significantly diminished phosphate incorporation ( Figure 2C ), thus suggesting that Ser150 (previously reported as a p21-dependent protein kinase site 31 ) and the serine pair at 23/24 (the canonical PKA doublet 32 ) are the principal phosphoacceptor sites. We tested whether cTnI was also a good AMPK substrate when reconstituted with human cardiac troponin T (cTnT) and troponin C (cTnC) to form troponin complex. cTnI was indeed found to be phosphorylated in whole troponin ( Figure  2D ); furthermore, experiments using whole human cardiac troponin reconstituted using cTnI phosphorylation site mutants confirmed that the serine residues at positions 150 (principally) and 23/24 are almost the exclusive targets of AMPK, with the triple mutant in which serines 23, 24, and 150 were mutated having only 4% phosphate incorporated compared with wild-type ( Figure 2D ).
cTnI-derived peptides containing the residues Ser23/24 and ser150 were synthesized and treated with His-AMPK ␣1(1-312) activated by LKB1/ STRAD/MO25. High resolution top-down mass spectrometry of the treated peptides confirmed their identity and revealed that both peptides were monophosphorylated (data not shown). The experimental mass (1695.840 Da) of the monophosphorylated peptides containing Ser150 matched well the calculated mass (1695.842 Da). The fragmentation data from electron capture dissociation (ECD) unequivocally located the phosphorylation site at residue Ser150, since the fragment ions containing Ser150 (ie, pc8-pc13 and pc12-pc13) were detected mono- phosphorylated and never unphosphorylated ( Figure 3A ). The peptides containing Ser23/24 were detected exclusively monophosphorylated (experimental and calculated masses of 1758.875 Da and 1758.879 Da, respectively) without detection of bisphosphorylated forms (data not shown). ECD fragmentation unambiguously located the phosphoyl moiety at either Ser23 or Ser24 ( Figure 3B ), as the fragment ions containing Ser23/24 were detected only monophosphorylated (ie, pc8, pc10-pc13, pz9 -11), whereas the fragment ions not containing Ser23/24 were detected only unphosphorylated (c4 -5). Moreover, because the fragment ion containing Ser23/24 but not Tyr26/Tyr29 (ie, pc8) was never detected unphosphorylated, possible phosphorylation of the tyrosine residues is ruled out.
Ser150 of cTnI Is Phosphorylated on AMPK Activation in Whole Hearts
To test whether Ser150 of cTnI is phosphorylated in situ, we examined cTnI in Langendorff-perfused hearts that had undergone a 30-minute period of global ischemia, conditions under which it has been established that AMPK is strongly activated. 10 Phosphorylation of cTnI at Ser150 was determined by western blotting of whole heart extracts using a phosphospecific antibody generated against a synthetic phosphorylated peptide. Weak staining was observed in control hearts using this antibody, but this was significantly increased in ischemic heart tissue (4.93Ϯ0.49 greater than control, nϭ3, PϽ0.05) (Figure 4 ). The level of Thr172 phosphorylation of the AMPK ␣ subunits was increased in the ischemic tissue (3.35Ϯ0.79 greater than control, nϭ3, PϽ0.05).
Effect of AMPK Phosphorylation on In Vitro Function of cTnI
To investigate how AMPK phosphorylation of cTnI affects in vitro myofilament function, the Ca 2ϩ -regulation of actintropomyosin-activated myosin S-1 ATPase activity by troponin was examined using phosphorylated cTnI and specific cTnI phosphorylation mimics in which phosphorylatable serines were replaced by aspartates. Wild-type thin filaments composed of actin, tropomyosin, and troponin activated myosin S-1 ATPase activity in a Ca 2ϩ -dependent manner with pCa 50 of 6.03Ϯ0.02 (nϭ3) and Hill coefficient, n H , a measure of cooperativity, 1.38Ϯ0.06 (nϭ3) ( Figure 5A) . Equivalent experiments using troponin phosphorylated by AMPK gave regulation with similar Ca 2ϩ -sensitivity and cooperativity but depressed maximum activation (6.45Ϯ0.07 seconds Ϫ1 compared with 7.89Ϯ0.04 seconds Ϫ1 for wildtype; nϭ3; PϽ0.05). As we have shown above, AMPK phosphorylation modifies cTnI at more than 1 site, and analysis of site-specific phosphorylation mimics was there- Figure 5B ). In contrast, troponin reconstituted with Ser23Asp/Ser24Asp cTnI resulted in regulation with profoundly reduced Ca 2ϩ sensitivity and maximally activated rate ( Figure 5B ). ATPase regulation by troponin reconstituted using the triple phosphomimic, in which Asp residues replaced Ser at positions 23, 24, and 150, showed significantly reduced Ca 2ϩ sensitivity and maximally activated rate compared with wild-type (PϽ0.05) ( Figure 5B) ; however, these parameters were both significantly elevated compared with the Ser23Asp/Ser24Asp mutant (PϽ0.05), suggesting (as with the comparison of wild-type and Ser150Asp cTnI) that the effect of Ser150 modification is to increase Ca 2ϩ sensitivity. The effect of site-specific cTnI phosphomimics on the regulation of force generation was examined using demembraneated mouse trabeculae in which the endogenous troponin was displaced using excess reconstituted recombinant human troponin. Compared with trabeculae reconstituted with wild-type troponin, trabeculae containing Ser150Asp cTnI showed significantly increased Ca 2ϩ -sensitivity of force generation (wild-type pCa 50 ϭ5.62Ϯ0.03, nϭ6; Ser150Asp pCa 50 ϭ5.73Ϯ0.05, nϭ6; PϽ0.05) ( Figure 5C ). In contrast, trabeculae reconstituted with troponin containing Ser23Asp/ Ser24Asp/Ser150Asp cTnI showed Ca 2ϩ -sensitivity slightly lower than wild-type (pCa 50 ϭ5.57Ϯ0.03, nϭ3; PϭNS), compared with wild-type (PϽ0.05, compared with Ser150). There was no significant difference in maximum Ca 2ϩ -activated force between the groups; however, the Hill coefficient of Ser150Asp (n H ϭ2.65Ϯ0.25, nϭ6) was significantly lower than both wild-type (n H ϭ3.77Ϯ0.26, nϭ6) and the triple phosphomimic (n H ϭ3.86Ϯ0.27, nϭ3) (PϽ0.05 for both).
Effects of AMPK Activation on cTnI Phosphorylation and Shortening in Murine LV Myocytes
An increase in myofilament Ca 2ϩ sensitivity suggests that AMPK activation may be involved in the regulation of myocardial function. We examined this hypothesis by investigating the effect of AMPK agonist AICAR on cTnI phosphorylation and contractile function in LV myocytes isolated from mouse hearts.
Treatment with 2 mmol/L AICAR resulted in phosphorylation of cTnI at Ser150 (Ͼ5-fold increase compared with control), as determined by Western blotting ( Figure 6A ). Preincubation of LV myocytes with AMPK inhibitor compound C (10 mol/L, 10 minutes at 37°C) attenuated the effect of AICAR on cTnI phosphorylation at Ser150; incubation with AICAR (or with AICAR plus compound C) did not change the phosphorylation status of Ser23/24 ( Figure 6A) .
Myocyte contractility and Ca 2ϩ dynamics were measured in LV myocytes loaded with Fura-2 ( Figure 6B through 6D) . Incubation with AICAR for 15 minutes was found to significantly increase cell shortening without changing the amplitude of Ca 2ϩ transients (Pϭ0.01 and Pϭ0.7, nϭ13, respectively; Figure 6B and 6C ), suggesting an increase in myofilament Ca 2ϩ sensitivity by AMPK activation. Under these conditions, AICAR shortened the time constant of decay of Ca 2ϩ transients (tau) but did not affect myocyte relaxation (Pϭ0.01 and Pϭ0.7, nϭ13, respectively; Figure  6B and 6D).
Contractility was also measured in LV myocytes in the absence of Fura-2. Under these conditions ( Figure 6E) , AICAR significantly prolonged LV myocyte relaxation (Fig-Figure 3 ure 6E, Pϭ0.009, nϭ11) and tended to increase cell shortening ( Figure 6E, Pϭ0.6, nϭ11 ). Compound C preincubation for 10 minutes abolished the effect of AICAR on time to 50% relaxation (TR50) over the same time course ( Figure 6E , Pϭ0.8 between compound C and compound CϩAICAR, nϭ9). Taken together, these results suggest that AMPK activation results in increased myocardial contractile function, mediated by an increase in myofilament Ca 2ϩ sensitivity.
Discussion
A yeast 2-hybrid screen of a human cardiac cDNA library using the unique N-terminal extension of AMPK ␥2 as bait identified cTnI as an interactor. Our subsequent work demonstrated that cTnI is a novel substrate for AMPK and that the principal in vitro phosphorylation site is Ser150. This site is phosphorylated on ischemia in whole hearts, and the functional consequence of Ser150 modification at the myofilament level is increased Ca 2ϩ sensitivity. Furthermore, on incubation of isolated cardiomyocytes with the AMPK activator AICAR, this site is phosphorylated and the myocyte relaxation time is increased. We propose that AMPK modification of troponin represents a novel mechanism for regulating cardiac contractility.
The initial screen produced a relatively low yield of putative interactors with 5 individual genes identified. Of the singly represented clones ( Table) , the function of FARP1 (encoding a protein identified in chondrocytes 33 ), PSMD10 (encoding a proteasome subunit containing 6 ankyrin repeat domains 34 ), and SKIIP (encoding a nuclear protein that interacts with the Vitamin D receptor 35 and the SKI oncoprotein 36 ) in cardiac cells is poorly understood. However, ANKRD1 encodes cardiac ankyrin repeat protein (CARP), which has been reported to be both a nuclear protein in the cardiomyocyte, interacting with the ubiquitous transcription factor YB-1, 37 and also found in the myofibrillar I-band region, specifically associated with the N2A region of titin, where it is believed to form part of a N2A stretch sensingsignaling complex along with p94/calpain-3 and myopalladin. 38 CARP expression increases profoundly on various cardiac insults and it is a recognized hypertrophic marker 39 ; mutations in ANKRD1 have also been reported as causes of hypertrophic and dilated cardiomyopathies. 40, 41 This was clearly an interesting putative interactor; however, preliminary work examining possible phosphorylation of CARP found it to be a poor AMPK substrate and attempts at coimmunoprecipitation of CARP and AMPK ␥2 were unsuccessful (data not shown).
Our identification of cTnI, a major cardiac phosphoprotein, as a putative interactor with the N-terminus of AMPK ␥2, prompted us to test whether cTnI was a substrate for the AMPK holoenzyme. It was found that cTnI is indeed phosphorylated by AMPK at high efficiency in vitro, showing a similar initial rate of phosphorylation as the SAMS peptide test substrate. As revealed by site-specific mutants and mass spectrometry analysis of synthetic peptides phosphorylated by AMPK, the principal phosphorylation site is Ser150 with the Ser23/24 doublet also being phosphorylated in vitro. Importantly, we show that Ser150 phosphorylation occurs in situ in isolated hearts on AMPK activation during ischemia (Figure 4 ). Although the initial cTnI interaction was identified using the ␥2 bait, at least in vitro cTnI is also a good substrate for ␥1-containing AMPK (Figure 2A ). Given the current lack of published data on the localization of different AMPK isoforms in cardiomyocytes, it is not clear which complexes (␥2-containing or ␥1-containing or both) are concentrated in the vicinity of the contractile apparatus to account for the observed phosphorylation of cTnI in intact hearts and isolated myocytes (Figures 4 and 6) .
Although the effect of in vitro phosphorylation of cTnI by AMPK on the regulation of actin-activated myosin ATPase is modest ( Figure 5A ), the use of site-specific phosphomimics showed that a significant increase in the Ca 2ϩ sensitivity of both ATPase activity in vitro and force regulation in demembraneated trabeculae was caused by Ser150 modification (Figure 5B and 5C ). Ser150 of cTnI has previously been shown to be phosphorylated in vitro by p21-dependent kinase. 31 Consistent with AMPK phosphorylation ( Figure  5A) , modification by p21-dependent kinase was also found to increase contractile Ca 2ϩ sensitivity. Ser150 lies at the N-terminus of the so-called switch peptide region (amino acids 148 -163), and C-terminal of the well-characterized inhibitory peptide sequence (residues 137 and 148), which binds to actin at low Ca 2ϩ concentrations and inhibits activation of actomyosin ATPase. 27 The switch peptide binds to a hydrophobic pocket within the N-terminal domain of cTnC in the presence of Ca 2ϩ and induces opening of the domain. 42 The incorporation of a phosphate group at Ser150 may increase Ca 2ϩ sensitivity by altering the switch peptide-cTnC interaction.
AICAR significantly increased myocyte contractility without changing the amplitude of Ca 2ϩ transient ( Figure 6B and (Pϭ0.07, nϭ14 ). E, Mean fractional shortening and mean time to 50% relaxation (TR50) in LV myocytes in the absence of Fura-2 and paced at 3 Hz; control (Ctr) or after 15-minute incubation with 2 mmol/L AICAR, in absence or presence of 10 mol/L compound C. AICAR significantly prolonged TR50 (Pϭ0.01, nϭ11) and tended to increase percent cell shortening (Pϭ0.6, nϭ11). Compound C prevented AICAR-induced prolongation of TR50. 6C). In addition, despite the time constant of the decay of Ca 2ϩ transient being faster, TR50 remained unchanged (Figure 6 B and 6D) . These results strongly suggest that AICAR positively regulates myocyte contractility by increasing myofilament Ca 2ϩ sensitivity. In LV myocytes in the absence of Fura-2, AICAR significantly prolonged relaxation but did not induce significant increase in myocyte cell shortening. It is known that AMPK activation exerts various functions in cardiac myocytes; for example, it can inhibit the Na ϩ -H ϩ exchanger 43 and therefore the negligible effect of AICAR on myocyte shortening in Fura-2 unloaded conditions may represent combined effects on myocyte function. Furthermore, AICAR is known to have AMPK-independent effects: for example, in skeletal muscle AICAR can increase both phosphorylation of acetyl-coA carboxylase 2 and rates of fatty acid oxidation and reduce malonyl-CoA levels independent of AMPK 44 and can activate glycogen phosphorylase directly in fibroblasts. 45 There is emerging evidence that there is considerable interplay between the O-GlcNAcylation and phosphorylation pathways. 46, 47 In an analysis of in vivo O-GlcNAcylation of myocardial proteins, it was found that Ser150 of cTnI was modified. 48 This raises the possibility of cross-talk between AMPK phosphorylation and O-GlcNAcylation signals at this residue, possibly fine tuning cTnI-mediated contractile regulation.
Although this is the first report of AMPK modification of troponin in cardiac myocytes, the enzyme has previously been linked to the regulation of motile processes in both nonmuscle and smooth cells. The AMPK-null mutation in Drosophila is lethal, producing severe defects in cell polarity and mitosis; it was shown that nonmuscle myosin regulatory light chain was phosphorylated directly by AMPK, and the expression of a phosphomimetic light chain was found to rescue the cell polarity and mitosis phenotype. 49 AMPK phoshorylates and desensitizes smooth muscle myosin light chain kinase 50 and has been shown to be involved in the regulation of Drosophila visceral smooth muscle via myosin light chain phosphorylation. 51 In mammalian cells, both the activated ␣ subunit and the ␥2 subunit have been localized to distinct position in the cytokinetic apparatus, 52, 53 and in epithelial cells the kinase has also been shown to mediate reorganization of the actin cytoskeleton. 54 Troponin has also been suggested to act as an A-kinase anchoring protein, in this case via interaction with cTnT. 55 The disease-causing PRKAG2 mutations probably cause an increase in basal AMPK activity 56 ; thus, if cTnI is a physiological substrate for ␥2-containing AMPK, PRKAG2 mutations would be predicted to increase Ca 2ϩ sensitivity of contractile regulation and this may contribute to disease pathogenesis. This change in contractile function is qualitatively the same as that caused by mutations in cTnI and other thin-filament proteins that cause hypertrophic cardiomyopathy. 57 The identification of cTnI as an AMPK substrate may also have broader relevance. AMPK in the heart is most markedly activated during ischemia and on exercise 10, 12 ; hence, AMPK phosphorylation may contribute to the altered contractile changes observed during, and recovery from, ischemic episodes. For example, extended relaxation duration is observed in myocardial stunning in humans and largeanimal models. 58 -60 
